Logo

Laura Clague

Oct 31, 2018

Laura Clague has been appointed to the board of directors of Fluidigm. She is the CFO of Retrophin. Previously, she was the CFO of the San Diego and Ohio operations of Amylin Pharmaceuticals, following the company's acquisition by Bristol-Myers Squibb. Prior to that, she was vice president, corporate controller, and principal accounting officer at Amylin, as well as CFO of Amylin's collaboration with Eli Lilly and Company. Clague holds a BS in business administration from Menlo College.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.